Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 13;2(5):e00307-17.
doi: 10.1128/mSphere.00307-17. eCollection 2017 Sep-Oct.

A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection

Affiliations

A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection

Arifa S Khan et al. mSphere. .

Abstract

The capability of high-throughput sequencing (HTS) for detection of known and unknown viruses makes it a powerful tool for broad microbial investigations, such as evaluation of novel cell substrates that may be used for the development of new biological products. However, like any new assay, regulatory applications of HTS need method standardization. Therefore, our three laboratories initiated a study to evaluate performance of HTS for potential detection of viral adventitious agents by spiking model viruses in different cellular matrices to mimic putative materials for manufacturing of biologics. Four model viruses were selected based upon different physical and biochemical properties and commercial availability: human respiratory syncytial virus (RSV), Epstein-Barr virus (EBV), feline leukemia virus (FeLV), and human reovirus (REO). Additionally, porcine circovirus (PCV) was tested by one laboratory. Independent samples were prepared for HTS by spiking intact viruses or extracted viral nucleic acids, singly or mixed, into different HeLa cell matrices (resuspended whole cells, cell lysate, or total cellular RNA). Data were obtained using different sequencing platforms (Roche 454, Illumina HiSeq1500 or HiSeq2500). Bioinformatic analyses were performed independently by each laboratory using available tools, pipelines, and databases. The results showed that comparable virus detection was obtained in the three laboratories regardless of sample processing, library preparation, sequencing platform, and bioinformatic analysis: between 0.1 and 3 viral genome copies per cell were detected for all of the model viruses used. This study highlights the potential for using HTS for sensitive detection of adventitious viruses in complex biological samples containing cellular background. IMPORTANCE Recent high-throughput sequencing (HTS) investigations have resulted in unexpected discoveries of known and novel viruses in a variety of sample types, including research materials, clinical materials, and biological products. Therefore, HTS can be a powerful tool for supplementing current methods for demonstrating the absence of adventitious or unwanted viruses in biological products, particularly when using a new cell line. However, HTS is a complex technology with different platforms, which needs standardization for evaluation of biologics. This collaborative study was undertaken to investigate detection of different virus types using two different HTS platforms. The results of the independently performed studies demonstrated a similar sensitivity of virus detection, regardless of the different sample preparation and processing procedures and bioinformatic analyses done in the three laboratories. Comparable HTS detection of different virus types supports future development of reference virus materials for standardization and validation of different HTS platforms.

Keywords: 454 Roche; Illumina; adventitious viruses; high-throughput sequencing; spiking study; virus detection.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Khan AS, King KE, Brack K, Cassart J-P, Chiu C, Dehghani H, Duncan P, Jaing C, Kolman J, Munroe D, Palermo A, Plavsic M, Sampath R, Slezak T, Takle G, Taliaferro LP, Toso E, Vacante D, Willkommen H. 2015. Emerging methods for virus detection. PDA technical report no. 71 Parenteral Drug Association, Bethesda, MD.
    1. Khan AS. 2010. Testing considerations for novel cell substrates: a regulatory perspective. PDA J Pharm Sci Technol 64:426–431. - PubMed
    1. Khan AS. 2011. Current testing methods and challenges for detection of adventitious viruses. PDA J Pharm Sci Technol 65:627–633. doi: 10.5731/pdajpst.2011.00831. - DOI - PubMed
    1. Khan AS, Lubiniecki A, King KE. 2012. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3 4, 2011, Rockville, MD. PDA J Pharm Sci Technol 66:502–511. doi: 10.5731/pdajpst.2012.00895. - DOI - PubMed
    1. Mallet L, Gisonni-Lex L. 2014. Need for new technologies for detection of adventitious agents in vaccines and other biological products. PDA J Pharm Sci Technol 68:556–562. doi: 10.5731/pdajpst.2014.01012. - DOI - PubMed